Contralateral prophylactic mastectomy for patients with unilateral breast cancer

Todd Tuttle, Elizabeth Habermann, Anasooya Abraham, Tim Emory, Beth Virnig

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Patients with unilateral breast cancer are at increased risk of developing a second cancer in the contralateral breast. Some women choose contralateral prophylactic mastectomy (CPM) to prevent cancer in the contralateral breast. Several studies have demonstrated that CPM significantly decreases the occurrence of contralateral breast cancer. However, the effectiveness of CPM at reducing breast cancer mortality is not as clear. Moreover, CPM is not risk free and patients may need to undergo additional surgical procedures, especially if reconstruction is performed. Nevertheless, most patients are satisfied with their decision to undergo CPM. Alternatives to CPM include close surveillance with clinical breast examination, mammography and possibly breast magnetic resonance imaging. Endocrine therapy with tamoxifen or a romatase inhibitors significantly reduces the risk of contralateral breast cancer and may be more acceptable than CPM for some patients. The decision to undergo CPM is complex and many factors likely contribute to its use. Future prospective studies are critically needed to evaluate the decision-making processes leading to CPM.

Original languageEnglish (US)
Pages (from-to)1117-1122
Number of pages6
JournalExpert review of anticancer therapy
Issue number8
StatePublished - Aug 2007


  • Aromatase inhibitor
  • Breast cancer
  • Breast magnetic resonance imaging
  • Contralateral prophylactic mastectomy
  • Prevention
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Contralateral prophylactic mastectomy for patients with unilateral breast cancer'. Together they form a unique fingerprint.

Cite this